New nanomedicines for a more efficient and less aggressive treatment of prostate cancer

In Europe, prostate cancer is the most common type of cancer among men with an incidence greater than 100 cases per 100,000 individuals. Furthermore, it is currently the second most common cause of cancer-related deaths among men. This pathology mainly affects elderly men: nine in 10 deaths take place after 65 years of age. Therefore, it represents a very serious […]

Continue reading »

Japanese study finds concerning trends in cervical cancer and treatment response

Cervical cancer rates can be greatly reduced through preventive measures against the human papillomavirus (HPV) along with proactive cancer screening. Japan may be showing how ignoring that knowledge could prove hazardous, as it is the only advanced economy in which the cervical cancer rate is increasing. New research adds further nuance to this situation. Researchers centered at Osaka University examined […]

Continue reading »

Discovery could improve cystic fibrosis treatment

Researchers exploring the effects of a long-standing treatment for cystic fibrosis have discovered a potential new target for drugs to treat the disease, which has no cure and typically cuts decades off the lives of patients. The research, a collaboration between the University of Saskatchewan in Canada and UC Berkeley, is based on a unique method developed by the Canadian […]

Continue reading »

Research team documents potential new treatment path for breast cancer

Immunotherapies that take off the “brakes” on the adaptive anti-tumor response have worked well in melanoma and lung cancer but less so in breast cancers. That could change. A Vanderbilt team led by John Wilson, assistant professor of chemical and biomolecular engineering, and Rebecca Cook, associate professor of cell and developmental biology, activated innate immunity in breast cancer cells and […]

Continue reading »

FDA approves drugs for treatment of two rare blood diseases

(HealthDay)—Two drugs have been approved by the U.S. Food and Drug Administration for the treatment of rare blood diseases, the agency announced Friday. Elzonris (tagraxofusp-erzs) infusion was granted the first approval for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and children aged 2 years and older. Researchers investigated the efficacy of Elzonris in two patient cohorts […]

Continue reading »

Study evaluates efficacy and safety of pancreatic cancer treatment in complex patient care cases

Gemcitabine given in combination with nab-paclitaxel is the standard of care for patients with advanced pancreatic cancer. This practice, however, rests on data obtained from several recent clinical trials enrolling patients with pancreatic cancer who skewed younger and in better overall condition than most. Currently, there is limited data regarding the management of patients who are older and in worse […]

Continue reading »

Study holds promise for new pediatric brain tumor treatment

New research published in Nature Communications from scientists at Huntsman Cancer Institute (HCI) at the University of Utah (U of U), in collaboration with the Stanford University School of Medicine, shows a specific protein regulates both the initiation of cancer spreading and the self-renewal of cancer cells in medulloblastoma, a type of pediatric brain cancer. Among children’s cancers, brain cancer […]

Continue reading »
1 2 3 5